Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Summary

This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.

Timeline

Start

2023-02-23

Primary completion

2024-12-18

Completion

2024-12-18

Outcome

Outcome not reported

Stopped (Enrollment): “Due to changes in the treatment landscape, the study faced significant recruitment challenges. As no patients were enrolled, the sponsor requested study closure”

Drugs

Indications